Jump to Main Content

FDA Alerts

FDA Approves Emicizumab-kxwh for Prevention and Reduction of Bleeding in Patients With Hemophilia A With Factor VIII Inhibitors

The Food and Drug Administration approved emicizumab-kxwh (HEMLIBRA®, Genentech, Inc.) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.